Integrichain Blog


April 28, 2024

Asembia Specialty Pharmacy Summit 2024

Eca41727 E0f6 43b6 Bf2c Bcd29ef32125

Join us at the 2024 Asembia Conference

IntegriChain is a proud silver sponsor and exhibitor at this year’s Asembia Specialty Pharmacy Summit on April 28 – May 2, 2024 at the Wynn & Encore in Las Vegas. Stop by Booth 1414 during the show to discuss how we can connect the commercial, financial, and operational dimensions of drug access and profitability, from strategy to operational execution.

Whether you are an emerging pharmaceutical manufacturer looking to operationalize their drug commercialization strategy for their first therapy, a mid-market firm planning to enter a new therapeutic category, or a large pharma tasked with reduce their revenue leakage and Gross-to-Net (GTN) “bubble,” our team will be on hand with discuss solutions to optimize pricing, access and channel strategies with reliable data. 

Senior Vice President and Managing Partner, Consulting

William Roth
Senior Vice President and Managing Partner, Consulting


Partner, Blue Fin Group

Bruce Phelan
Partner, Blue Fin Group



Session: Commercial Considerations: Launching and Defending Against Biosimilars and Specialty Generics

Description: The market for Pharmacy Benefit Specialty Generics and Biosimilars have not been the boon that the market expected. Medicaid is likely to block them because the reference product is already either free or a very low cost due to the brand taking price increases and penalties applied via the CPI-U penalty.

In 2025 the incentive for Medicare Part D patients to use the generics goes away thanks to the $2000/year Out of Pocket Cap (which is the only real market that the current Specialty Generics have). And Commercial Plans don’t really want to support them because it risks massive hits to their rebate dollars. From research conducted by Blue Fin Group, Humira alone is between 25-40% of a PBMs rebates. Come hear the tailwinds and headwinds to launch and defend against.

Date/Time: Tuesday, April 30, 2024 – 1:00 PM 

Check back for updates, and learn more about the pharmaceutical industry’s need for a more balanced commercialization approach. 

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article